App-Quantinova.ai

FRONT-MIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING EFFICACY AND SAFETY OF R-CHOP + TAFASITAMAB + LENALIDOMIDE VS R-CHOP ALONE FOR NEWLY-DIAGNOSED HIGH-RISK DLBCL

Umberto Vitolo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Lenalidomide

EFFECT OF PEGCETACOPLAN ON QUALITY OF LIFE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: WEEK 48 OF PEGASUS PHASE 3 TRIAL COMPARING PEGCETACOPLAN TO ECULIZUMAB

Alexander Rth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Paroxysmal nocturnal hemoglobinuria

Eculizumab

APPRAISAL OF THE CONSISTENT USE AND REPORTING OF PATIENT-REPORTED OUTCOMES IN MULTIPLE MYELOMA CLINICAL TRIALS: DOES IT MATTER?

Edward Laane - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

N/A

CLONAL HAEMATOPOIESIS: USING LONGITUDINAL COHORT DATA TO STUDY THE AGEING HUMAN HAEMATOPOIETIC SYSTEM

Kristina Kirschner - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

SAFETY AND EFFICACY OF VOXELOTOR IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE AGED 4-11 YEARS

Jeremie Estepp - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Hydroxyurea

VENETOCLAX-OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION-BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY

Othman Al-Sawaf - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Obinutuzumab

LOCAL SAFETY STANDARDS FOR INVASIVE PROCEDURES (LOCSSIPS) IN HAEMATOLOGY

Zeba Ahmed - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

MANAGEMENT OF MENINGOCOCCAL DISEASE RISK IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON COMPLEMENT INHIBITORS: 18 YEARS’ EXPERIENCE FROM THE UK NATIONAL PNH SERVICE IN LEEDS

Louise Arnold - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Paroxysmal nocturnal hemoglobinuria

Penicillin

CAR-T CELL THERAPY FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A COCHRANE SYSTEMATIC REVIEW

Moritz Ernst - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Courtney DiNardo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

INCIDENCE OF VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN ENGLAND BASED ON HEALTHCARE RESOURCE GROUP CODES AND HOSPITAL EPISODE STATISTICS© DATA

James Angus - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic veno-occlusive disease with immunodeficiency

Defibrotide

DIAGNOSTIC YIELD AND SAFETY OF IMAGE-GUIDED PERCUTANEOUS SPLENIC BIOPSY – A TWO-CENTRE EXPERIENCE FROM THE EAST OF ENGLAND

Francis Anyanwu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies

N/A

QUANTIFYING THE HEALTHCARE RESOURCE USE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS IN ENGLAND

James Farrell - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

N/A

DOES INTENSIVE CHEMOTHERAPY REALLY HELP OLDER DLBCL PATIENTS LIVE LONGER?

Dominic Gordon-Walker - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

chlorambucil

CD19 CAR-T IN LESS FIT PATIENTS WITH R/R HIGH-GRADE LYMPHOMA

Andrea Kuhnl - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Axicabtagene ciloleucel

TREATMENT OF IMMUNE THROMBOCYTOPENIA IN THE COVID-19 ERA: FOSTAMATINIB, AN ORAL SPLEEN TYROSINE KINASE INHIBITOR

Nichola Cooper - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Immune thrombocytopenia

Fostamatinib

RAVULIZUMAB AND ECULIZUMAB REDUCE TRANSFUSIONS IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: EVIDENCE FROM THREE REAL-WORLD DATABASES: TRINETX US EMR, TRINETX US CLAIMS AND KOMODO HEALTH

Ioannis Tomazos - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Paroxysmal nocturnal hemoglobinuria

Eculizumab

MULTIPLE MYELOMA TREATMENT DECISIONS FROM THE PATIENT PERSPECTIVE

Matthew Lyall - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

HEMATOLOGIC ADVERSE EVENTS AND MANAGEMENT STRATEGIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION RECEIVING ORAL AZACITIDINE (ORAL-AZA) IN THE PHASE 3 QUAZAR AML-001 TRIAL

Farhad Ravandi - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

Toby Eyre - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Filters

45280 Abstracts